Skip to main
CDNA

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

CareDx Inc demonstrated a positive business outlook with a 21% year-over-year revenue growth in Q3 driven by a 13% increase in volume and a 5% lift in average selling prices (ASPs). The company achieved its highest cash collections in history in October and significantly expanded its sales force by approximately 50%, which is poised to further enhance volume growth over the coming months. Additionally, CareDx reported a solid performance, achieving GAAP net income positivity and raising its revenue guidance, indicative of strong operational momentum.

Bears say

CareDx Inc reported Q3 2025 testing volumes of 50,000, which represented a 13% year-over-year increase but fell short of expectations, indicating a slowdown in growth despite surveillance testing expanding by approximately 20%. The stock has faced downward pressure, trading at only 1.4 times the 2026 revenue estimate of $415 million, which is significantly below historical averages of 3-7 times and far less than competitors in the diagnostics sector valued at 9-10 times. Additionally, the company's reliance on successful commercialization of new diagnostic solutions is uncertain amidst a backdrop of management changes over the past three years, contributing to a cautious outlook on its growth trajectory.

CareDx (CDNA) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 6 analysts, CareDx (CDNA) has a Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.